Immunome Inc. (IMNM) stock
IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.61−0.17 (-1.01%)
Close on Nov 19, 2026Market cap $1.89BP/E –Yield –
Immunome free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Immunome's free cash flow for the twelve months ending Mar 31, 2026 was -$205.52M. For fiscal 2025 it was -$200.60M. The highest annual figure on record is -$8.40M in fiscal 2023.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$200.60M | – |
| FY2024 | Dec 31, 2024 | -$117.97M | – |
| FY2023 | Dec 31, 2023 | -$8.40M | – |
| FY2022 | Dec 31, 2022 | -$28.94M | – |
| FY2021 | Dec 31, 2021 | -$18.31M | – |
| FY2020 | Dec 31, 2020 | -$12.72M | – |
| FY2019 | Dec 31, 2019 | -$9.83M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$61.64M | – |
| Q4 FY2025 | Dec 31, 2025 | -$51.95M | – |
| Q3 FY2025 | Sep 30, 2025 | -$41.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$50.31M | – |
| Q1 FY2025 | Mar 31, 2025 | -$56.72M | – |
| Q4 FY2024 | Dec 31, 2024 | -$43.19M | – |
| Q3 FY2024 | Sep 30, 2024 | -$35.71M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.74M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.33M | -155.4% |
| Q4 FY2023 | Dec 31, 2023 | -$17.81M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.01M | – |
| Q1 FY2023 | Mar 31, 2023 | $24.07M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.76M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.38M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.82M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.17M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.75M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.57M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.11M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.65M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.12M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.65M | – |
See a number that looks wrong?